As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Tectonic Therapeutic, Inc. The largest reported stake is Chen Yu's, at 6.2%. 5 filings are on record since November 14, 2025 (Schedule 13G, February 27, 2026).
Sell to companies like Tectonic Therapeutic, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Aberdeen Group plc · Sole voting: 0 · Shared voting: 484,887 · Sole dispositive: 0 · Shared dispositive: 484,887 · SCHEDULE 13G/A, 2026-10-29
- · Reporting person: TCG Crossover GP II, LLC · Sole voting: 0 · Shared voting: 584,882 · Sole dispositive: 0 · Shared dispositive: 584,882 · SCHEDULE 13G, 2026-02-27
- · Holder: Aberdeen Group plc · Percent: 6.1% · SCHEDULE 13G
- · Reporting person: EcoR1 Capital, LLC · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2025-11-14
- · Reporting person: Deep Track Capital, LP · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2025-11-14
Tectonic Therapeutic, Inc. has 5 Schedule 13D or 13G filings on record since 2025-11-14. 1 holder's latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 6.2% | 1,169,760 | SCHEDULE 13G, 2026-02-27 | 2026-02-12 | |
| Aberdeen Group plc | 2.48% | 484,887 | SCHEDULE 13G/A, 2026-10-29 | 2026-09-30 |
| EcoR1 Capital, LLC | 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Deep Track Capital, LP | 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
Holding shares or following this stake? See who's behind Tectonic Therapeutic, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Tectonic Therapeutic, Inc. and the records around it.
Tectonic Therapeutic, Inc. elsewhere on the record
- Leadership changes Apr 2026
- Who owns it
Companies that share a holder
- Aberdeen Group plc also filed stake reports on 12 other companies: Equillium, Inc. (Nov 2026), IMMUNIC, INC (Nov 2026), CODEXIS, INC. (Oct 2026)
- EcoR1 Capital, LLC also filed stake reports on 20 other companies: Mereo BioPharma Group plc (Aug 2026), Alto Neuroscience, Inc. (Jul 2026), Fulcrum Therapeutics, Inc. (Jun 2026)
- TCG Crossover GP II, LLC also filed stake reports on 21 other companies: ALX Oncology Holdings Inc. (Aug 2026), First Tracks Biotherapeutics, Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
Watch Tectonic Therapeutic, Inc.
Get an email when Tectonic Therapeutic, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Tectonic Therapeutic, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Tectonic Therapeutic, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Tectonic Therapeutic, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| TCG Crossover GP II, LLC | 0 | 584,882 | 0 | 584,882 | SCHEDULE 13G, 2026-02-27 |
| TCG Crossover Fund II, L.P. | 0 | 584,882 | 0 | 584,882 | SCHEDULE 13G, 2026-02-27 |
| TCG Crossover GP III, LLC | 0 | 584,878 | 0 | 584,878 | SCHEDULE 13G, 2026-02-27 |
| TCG Crossover Fund III, L.P. | 0 | 584,878 | 0 | 584,878 | SCHEDULE 13G, 2026-02-27 |
| Chen Yu | 0 | 1,169,760 | 0 | 1,169,760 | SCHEDULE 13G, 2026-02-27 |
| Aberdeen Group plc | 0 | 484,887 | 0 | 484,887 | SCHEDULE 13G/A, 2026-10-29 |
| abrdn Inc | 0 | 484,887 | 0 | 484,887 | SCHEDULE 13G/A, 2026-10-29 |
| EcoR1 Capital, LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2025-11-14 |
| Oleg Nodelman | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2025-11-14 |
| EcoR1 Capital Fund Qualified, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2025-11-14 |
| Deep Track Capital, LP | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2025-11-14 |
| Deep Track Biotechnology Master Fund, Ltd. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2025-11-14 |
| David Kroin | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2025-11-14 |
The latest filing identifies Tectonic Therapeutic, Inc. by CUSIP 878972108 and gives its principal executive office as 490 ARSENAL WAY, SUITE 210, WATERTOWN, MA 02472 (SCHEDULE 13G/A, 2026-10-29).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-11-14 | EcoR1 Capital, LLC | 0% | SCHEDULE 13G/A |
| 2025-11-14 | Deep Track Capital, LP | 0% | SCHEDULE 13G/A |
| 2026-01-29 | Aberdeen Group plc | 6.1% | SCHEDULE 13G |
| 2026-02-27 | Chen Yu | 6.2% | SCHEDULE 13G |
| 2026-10-29 | Aberdeen Group plc | 2.48% | SCHEDULE 13G/A |
Questions about who owns Tectonic Therapeutic, Inc.
Who owns Tectonic Therapeutic, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Tectonic Therapeutic, Inc.: Chen Yu (6.2%, Schedule 13G, filed 2026-02-27).
When did Chen Yu buy into Tectonic Therapeutic, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Chen Yu on this page is the Schedule 13G, filed 2026-02-27, reporting 6.2%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Tectonic Therapeutic, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| April 23, 2026 | Leadership change: Jessica Chutter appointed, Director | — | Leadership changes | Source |
| February 14, 2025 | Form D, private offering | $185.03M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Tectonic Therapeutic, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.